Current cervical cancer prevention strategies including cervical screening and prophylactic human papillomavirus vaccination: A review

Current Opinion in Oncology

Volumn 26, Issue 1, 2014, Pages 120-129

  Elfström, Klara Miriam ^a   Herweijer, Eva ^a   Sundström, Karin ^a   Arnheim Dahlström, Lisen ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

adverse events; cervical cancer screening; effectiveness; human papillomavirus vaccination; prevention

Indexed keywords

ACETIC ACID; LUGOL; VIRUS DNA; WART VIRUS VACCINE;

CANCER IMMUNIZATION; CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; COLPOSCOPY; CONDYLOMA ACUMINATUM; DRUG SAFETY; FAINTNESS; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; INJECTION SITE PAIN; PAPANICOLAOU TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SELF EVALUATION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VENOUS THROMBOEMBOLISM;

CLINICAL TRIALS AS TOPIC; FEMALE; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 84890555975     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000034     Document Type: Review

References (44)

1. Andrae B, Andersson TM, Lambert PC, et al. Screening and cervical cancer cure: Population based cohort study. BMJ 2012; 344:e900.
2. Fairley CK, Hocking JS, Gurrin LC, et al. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 2009; 85:499-502.
3. Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: Analysis of national sentinel surveillance data. Lancet Infect Dis 2011; 11:39-44.
4. Read TR, Hocking JS, Chen MY, et al. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011; 87:544-547.
5. Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: National surveillance data. BMJ 2013; 346:; f2032. Results from this study show large declines in genital wart diagnoses among heterosexual males that are most likely due to the herd immunity effect of vaccinating females
6. Ali H, Guy RJ, Wand H, et al. Decline in in-patient treatments of genital warts among young Australians following the national HPV vaccination program. BMC Infect Dis 2013; 13:140. This analysis focused on in-patient treatments of genital warts and found a decline in the vaccination period.
7. Brotherton JM, Fridman M, May CL, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: An ecological study. Lancet 2011; 377:2085-2092.
8. Baandrup L, Blomberg M, Dehlendorff C, et al. Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis 2013; 40:130-135. This analysis showed a significant decrease in genital warts following the introduction of the HPV vaccine. Incidence of other sexually transmitted infections was also measured and found to be stable or increasing, suggesting that the decrease in genital warts was due to vaccination not shifts in behavior.
9. Blomberg M, Dehlendorff C, Munk C, Kjaer SK. Strongly decreased risk of genital warts after vaccination against human papillomavirus: Nationwide follow-up of vaccinated and unvaccinated girls in Denmark. Clin Infect Dis 2013; 57:929-934. Similarly, this study also used individually linked data and showed a significant reduction in the occurrence of genital warts in vaccinated females.
10. Oliphant J, Perkins N. Impact of the human papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland Sexual Health Services. N Z Med J 2011; 124:51-58.
11. Leval A, Herweijer E, Arnheim-Dahlstrom L, et al. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis 2012; 206:860-866. This study evaluated the incidence of genital warts before and after HPV vaccination availability and showed a decrease in incidence among younger females following the introduction of the vaccine
12. Leval A, Herweijer E, Ploner A, et al. Quadrivalent human papillomavirus vaccine effectiveness: A Swedish national cohort study. J Natl Cancer Inst 2013; 105:469-474. This study used individually linked data to examine vaccine effectiveness in population and the effect of age-at-vaccination
13. Bauer HM, Wright G, Chow J. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: An analysis of California public family planning administrative claims data. Am J Public Health 2012; 102:833-835. This study from the United States used public family planning administrative data and showed a decline in genital wart diagnoses after the start of vaccination for both females and males
14. Flagg EW, Schwartz R, Weinstock H. Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010: Potential impact of human papillomavirus vaccination. Am J Public Health 2013; 103:1428-1435. This study showed decreases in genital wart diagnoses among females in the target age group and a levelling off of prevalence among males
15. Niccolai LM, Julian PJ, Meek JI, et al. Declining rates of high-grade cervical lesions in young women in Connecticut, 2008-2011. Cancer Epidemiol Biomarkers Prev 2013; 22:1446-1450. This is the first study from the United States to show a decline in cervical neoplasia following HPV vaccination
16. Powell SE, Hariri S, Steinau M, et al. Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. Vaccine 2012; 31:109-113. This study shows a reduction in HPV16/18-related CIN2 lesions among females who were vaccinated before their trigger Pap smear.
17. Immunise-Human Papillomavirus (HPV). Available from: Http://www.immunise. health.gov.au/internet/immunise/publishing.nsf/Content/immunise-hpv [Accessed 5 Jul 2013]
18. Uge 22-2012-EPI-NYT-Statens Serum Institut. Available from: Http://www.ssi.dk/Aktuelt/Nyhedsbreve/EPI-NYT/2012/Uge%2022%20-%202012.aspx [Accessed 8 Jul 2013]
19. Minist. Heal. Nz. HPV immunisation programme. Available from: Http://www.health.govt.nz/our-work/preventative-health-wellness/immunisation/ hpv-immu nisation-programme [Accessed 8 Jul 2013]
20. National, State, and Local Area Vaccination Coverage among Adolescents Aged 13-17 Years - United States, 2009. Available from: Http://www.cdc. gov/mmwr/preview/mmwrhtml/mm5932a3.htm [Accessed 28 May 2013]
21. Noninfluenza Vaccination Coverage Among Adults - United States, 2011. Available from: Http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6204a2. htm [Accessed 8 Jul 2013]
22. Naucler P, Ryd W, Tornberg S, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009; 101:88-99.
23. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007; 357:1579-1588.
24. Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012; 30 (Suppl 5): F88-F99.
25. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 2008; 100:492-501.
26. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: Joint European cohort study. BMJ 2008; 337: A1754.
27. Kitchener HC, Gilham C, Sargent A, et al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: Extended follow up in the ARTISTIC trial. Eur J Cancer 2011; 47:864-871.
28. Chumworathayi B, Blumenthal PD, Limpaphayom KK, et al. Effect of singlevisit VIA and cryotherapy cervical cancer prevention program in Roi Et, Thailand: A preliminary report. J Obstet Gynaecol Res 2010; 36:79-85.
29. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360:1385-1394.
30. Richman AR, Brewer NT, Liebman AK, et al. Optimising human papillomavirus self-testing for high risk women. Sex Transm Infect 2011; 87:118-122.
31. Rijkaart DC, Heideman DA, Coupe VM, et al. High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology. J Clin Microbiol 2012; 50:2390-2396.
32. Trope A, Sjoborg KD, Nygard M, et al. Cytology and human papillomavirus testing 6 to 12 months after ASCUS or LSIL cytology in organized screening to predict high-grade cervical neoplasia between screening rounds. J Clin Microbiol 2012; 50:1927-1935.
33. Dillner J, Kjaer SK, Wheeler CM, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: Randomised controlled trial. BMJ 2010; 341: C3493.
34. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301-314.
35. Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: Analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009; 199:805-814.
36. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009; 302:750-757.
37. Chao C, Klein NP, Velicer CM, et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Int Med 2012; 271:193-203.
38. Gee J, Naleway A, Shui I, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: Findings from the Vaccine Safety Datalink. Vaccine 2011; 29:8279-8284.
39. Klein NP, Hansen J, Chao C, et al. Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Arch Pediatr Adolesc Med 2012; 166:1140-1148. This study made use of the Kaiser Permanente data from the California, USA and found, again, no evidence of safety concerns among females in the vaccination ages.
40. Chao C, Jacobsen SJ. Evaluation of autoimmune safety signal in observational vaccine safety studies. Hum Vaccin Immunother 2012; 8:1302-1304. This observational study examined risk after quadrivalent HPV vaccination for 16 prespecified autoimmune diseases and found no safety signals.
41. Arnheim-Dahlstrom L, Pasternak B, Svanstrom H, et al. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: Cohort study. BMJ 2013; 347:f5906.
42. Levi M, Bonanni P, Burroni E, et al. Evaluation of bivalent human papillomavirus (HPV) vaccine safety and tolerability in a sample of 25 year old Tuscan women. Hum Vaccin Immunother 2013; 9:1407-1412. This study examined potential adverse events in women at the older limit of the vaccination ages (25) and found that the safety and tolerability did not differ much between older females and younger females (examined in other analyses).
43. Gasparini R, Bonanni P, Levi M, et al. Safety and tolerability of bivalent HPV vaccine: An Italian postlicensure study. Hum Vaccin 2011; (7 Suppl):136-146.
44. Heijstek MW, Scherpenisse M, Groot N, et al. Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: A prospective controlled observational cohort study. Ann Rheum Dis 2013.